硫酸沙丁胺醇联合喘可治治疗儿童支气管哮喘临床对照研究

A clinical control study of salbutamol sulphate plus chuankezhi in children bronchial asthma

目的探讨硫酸沙丁胺醇联合喘可治治疗儿童支气管哮喘急性发作的临床疗效及安全性。方法将84例支气管哮喘急性发作患儿，随机分为两组，每组42例。两组均口服硫酸沙丁胺醇缓释胶囊治疗，研究组在此基础上联合喘可治肌内注射治疗。观察1周。观察并分析治疗前及治疗1周末，两组临床症状及体征评分和肺功能指标检测结果。结果治疗后，两组呼吸困难、喘息、哮呜音症状评分均较治疗前显著降低（P〈0．05或0．01），研究组较对照组下降更显著（P〈0．01）；两组最大呼吸流量占预计值百分比和第1s用力呼气量占预计值百分比均较治疗前显著升高（P〈0．05或0．01），且研究组较对照组升高更显著（P〈0．01）。两组均未出现明显不良反应。结论硫酸沙丁胺醇联合喘可治治疗儿童支气管哮喘急性发作疗效显著，安全性高，显著优于单用硫酸沙丁胺醇治疗。

Objective To explore the efficacy and safety of salbutamol sulphate plus chuankezhi in children acute bronchial asthma. Methods Eighty four children with acute bronchial asthma were randomly as- signed to two groups of 42 ones each. Both groups took orally salbutamol sulfate sustained capsules, re- search group was plus chuankezhi intramscular injection treatment for 1 week. Efficacy, sign score and function test index of both groups were observe and analyzed before and after 1-week treatment. Results After treatment, dyspnea, gasping and wheezing sound scores of both groups lowered more significantly compared with pretreatment （P〈0.05 or 0.01） ,so did in research than in control group （P〈0.01） ; the percentage of peak expiratory flow and forced expiratory volume at the 1st second of prediction value heightened more significantly of both groups （P〈0.05 or 0.01）, so did in research than in control group （P〈0.01）. Both groups had no obvious adverse reactions. Conclusion Salbutamol sulphate plus chua- nkezhi has an advantage over single salbutamol sulphate in efficacy and safety in the treatment of children acute bronchial asthma.